The work goes on & the word spreads, page-7

“Importantly it captures the combination of HER-Vaxx with checkpoint inhibitors, an important immuno-oncology drug class generating multi-billion dollar returns for companies such as Merck, BMS and Genentech.”

To make it clearer they have combined Her-vaxx with their anti-PD1

We already know Her-vaxx bonds to the same sites as Trastuzumab (Herceptin) and Pertuzumab (Perjeta) and one more.

It’s the 3 hit combo and now the anti-PD1 could ne the final blow.